JNK1 inhibition reduces the expression of the anti-apoptotic proteins BCL2 and MCL1. (A) Protein expression of p-JNK1 and total JNK1 in primary human CLL cells after 4 h of SP600125 and CC-930 treatment (n = 3, shown CLL#8). (B) Protein expression of p-JNK1 and total JNK1 in primary human CLL cells after 8 h of L-JNKi treatment (CLL#34). (C) Protein expression of p-BCL2, total BCL2, p-MCL1, and total MCL1 in primary human CLL cells after 8 h of SP600125 and CC-930 treatment (CLL#26). (D) Protein expression of p-BCL2, total BCL2, p-MCL1, and total MCL1 in primary human CLL cells after 4 h of L-JNKi treatment (CLL#34). Blots are shown for one out of three CLLs per treatment. (E) Relative expression of pJNK1, pBCL2, and pMCL1 compared with β-actin and relative to the non-treatment control in CLL cells (n = 3) treated with the different JNK1 inhibitors (three CLLs per treatment, unpaired t test *P < 0.05; **P < 0.01, ***P < 0.001). (F) JNK1 expression and pBCL2/BCL2 expression in CLL cells treated with JNK1 siRNA15 and 16 or NoSi control for 24 h (CLL#34). (G) Relative expression of pBCL2 in CLL cells (n = 3) treated with siRNAs against JNK1 or NoSi compared with β-actin and normalized to the control group. Source data are available for this figure: SourceData F3.